Biocept, Inc. short interest in 2022
In 2022, Biocept, Inc.'s disclosed short interest ran from 2.21% of shares outstanding on 14 Jan 2022 to 0.43% on 30 Dec 2022, a change of -1.78 percentage points. The year's high was 2.30% on 28 Feb 2022 and its low 0.37% on 15 Nov 2022, averaging 1.19% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 3.73 days on 13 May 2022. Full history: Biocept, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023
2022 in figures
- Start of year
- 2.21% (14 Jan 2022)
- End of year
- 0.43% (30 Dec 2022)
- Change
- -1.78 pp
- High
- 2.30% (28 Feb 2022)
- Low
- 0.37% (15 Nov 2022)
- Average
- 1.19%
- Highest days to cover
- 3.73 (13 May 2022)
- SEC filings marked
- 9
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 2.21% | 1.68 | |
| 31 Jan 2022 | 2.24% | 2.24 | |
| 15 Feb 2022 | 2.03% | 2.72 | |
| 28 Feb 2022 | 2.30% | 2.97 | |
| 15 Mar 2022 | 2.02% | 2.28 | |
| 31 Mar 2022 | 2.19% | 3.20 | |
| 14 Apr 2022 | 2.04% | 3.05 | results (8-K), 10-K filed, results (8-K) |
| 29 Apr 2022 | 1.85% | 3.17 | |
| 13 May 2022 | 1.73% | 3.73 | |
| 31 May 2022 | 1.44% | 2.48 | 10-Q filed, results (8-K) |
| 15 Jun 2022 | 1.29% | 2.91 | |
| 30 Jun 2022 | 0.94% | 1.00 | |
| 15 Jul 2022 | 0.73% | 1.47 | |
| 29 Jul 2022 | 0.55% | 1.78 | |
| 15 Aug 2022 | 0.59% | 1.05 | |
| 31 Aug 2022 | 0.59% | 1.26 | |
| 15 Sep 2022 | 0.48% | 2.39 | |
| 30 Sep 2022 | 0.66% | 1.52 | |
| 14 Oct 2022 | 0.52% | 1.92 | |
| 31 Oct 2022 | 0.46% | 1.79 | |
| 15 Nov 2022 | 0.37% | 1.24 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 0.47% | 1.77 | 10-Q filed, results (8-K) |
| 15 Dec 2022 | 0.46% | 1.00 | |
| 30 Dec 2022 | 0.43% | 1.00 |
See also: Biocept, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.